{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T14:03:26Z","timestamp":1784383406771,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,18]]},"DOI":"10.7759\/cureus.112910","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:20:34Z","timestamp":1784380834000},"source":"Crossref","is-referenced-by-count":0,"title":["Slowing Mortality Improvements in Multiple Myeloma Despite Novel Therapies: Global Disparities by Sociodemographic Index, 1990-2023"],"prefix":"10.7759","author":[{"given":"Tapan","family":"Giri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeal","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima D","year":"2022","unstructured":"Dima D, Jiang D, Singh DJ, et al.. Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022, 14:4082. 10.3390\/cancers14174082","journal-title":"Cancers (Basel)"},{"key":"ref2","unstructured":"Darzalex (daratumumab). first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. (2016). Accessed: July 7, 2026: https:\/\/www.ahdbonline.com\/issues\/2016\/march-2016-vol-9-seventh-annual-payers-guide\/darzalex-daratumumab-first-anti-c...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2023.103920","article-title":"An overview of multiple myeloma: a monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities","volume":"31","author":"Abduh MS","year":"2024","unstructured":"Abduh MS. An overview of multiple myeloma: a monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities. Saudi J Biol Sci. 2024, 31:103920. 10.1016\/j.sjbs.2023.103920","journal-title":"Saudi J Biol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04033","article-title":"Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019","volume":"14","author":"Geng J","year":"2024","unstructured":"Geng J, Zhao J, Fan R, et al.. Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019. J Glob Health. 2024, 14:04033. 10.7189\/jogh.14.04033","journal-title":"J Glob Health"},{"key":"ref5","article-title":"Global Burden of Disease 2023 Results Tool","year":"2023","unstructured":"Global Burden of Disease 2023 Results Tool. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA; 2023."},{"key":"ref6","article-title":"Global Burden of Disease Study 2021 (GBD 2021) Socio-Demographic Index (SDI) 1950-2021","year":"2024","unstructured":"Global Burden of Disease Study 2021 (GBD 2021) Socio-Demographic Index (SDI) 1950-2021. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA; 2024."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1735565","article-title":"Trends in mortality rates associated with multiple myeloma in the United States, 1999-2023","volume":"15","author":"Jiang Y","year":"2025","unstructured":"Jiang Y, Liang G, Cao Y. Trends in mortality rates associated with multiple myeloma in the United States, 1999-2023. Front Oncol. 2025, 15:1735565. 10.3389\/fonc.2025.1735565","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22240-2","article-title":"Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021","volume":"25","author":"Diao X","year":"2025","unstructured":"Diao X, Ben T, Cheng S, Niu S, Gao L, Xia N. Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health. 2025, 25:1054. 10.1186\/s12889-025-22240-2","journal-title":"BMC Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00747-6","article-title":"Disparities in clinical trial enrollment- focus on CAR-T and bispecific antibody therapies","volume":"20","author":"Islam N","year":"2024","unstructured":"Islam N, Budvytyte L, Khera N, Hilal T. Disparities in clinical trial enrollment- focus on CAR-T and bispecific antibody therapies. Curr Hematol Malig Rep. 2024, 20:1. 10.1007\/s11899-024-00747-6","journal-title":"Curr Hematol Malig Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286518","article-title":"Risk perception of non-communicable diseases: a systematic review on its assessment and associated factors","volume":"18","author":"Jane Ling MY","year":"2023","unstructured":"Jane Ling MY, Ahmad N, Aizuddin AN. Risk perception of non-communicable diseases: a systematic review on its assessment and associated factors. PLoS One. 2023, 18:e0286518. 10.1371\/journal.pone.0286518","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131708","article-title":"Challenges, difficulties, and delayed diagnosis of multiple myeloma","volume":"15","author":"Zorlu T","year":"2025","unstructured":"Zorlu T, Kayer MA, Okumus N, Ula\u015f T, Dal MS, Altuntas F. Challenges, difficulties, and delayed diagnosis of multiple myeloma. Diagnostics (Basel). 2025, 15:1708. 10.3390\/diagnostics15131708","journal-title":"Diagnostics (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003949","article-title":"Global burden of multiple myeloma in older adults from 1990 to 2021 and modeled projection to 2050","volume":"112","author":"Hu H","year":"2026","unstructured":"Hu H, Zhang Y, Shao Z, Zhang Y, Song Q, Yang W, Wang B. Global burden of multiple myeloma in older adults from 1990 to 2021 and modeled projection to 2050. Int J Surg. 2026, 112:4588-603. 10.1097\/JS9.0000000000003949","journal-title":"Int J Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00795-w","article-title":"Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic","volume":"13","author":"Carmichael J","year":"2023","unstructured":"Carmichael J, Seymour F, McIlroy G, et al.. Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic. Blood Cancer J. 2023, 13:38. 10.1038\/s41408-023-00795-w","journal-title":"Blood Cancer J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes TM","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014, 32:2531-40. 10.1200\/JCO.2014.55.1028","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01340-7","article-title":"Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis","volume":"15","author":"Askari E","year":"2025","unstructured":"Askari E, Dispenzieri A, Buadi FK, et al.. Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis. Blood Cancer J. 2025, 15:133. 10.1038\/s41408-025-01340-7","journal-title":"Blood Cancer J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri A","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, et al.. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009, 23:215-24. 10.1038\/leu.2008.307","journal-title":"Leukemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508958-slowing-mortality-improvements-in-multiple-myeloma-despite-novel-therapies-global-disparities-by-sociodemographic-index-1990-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:20:35Z","timestamp":1784380835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508958-slowing-mortality-improvements-in-multiple-myeloma-despite-novel-therapies-global-disparities-by-sociodemographic-index-1990-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.112910","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,18]]}}}